ClinicalTrials.gg
CompletedNCT06132126Updated Jul 24, 2024

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

A Phase 1 interventional study of LY3938577 and Placebo in Healthy and Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-24.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company — 10 open to participants now, 21 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Eli Lilly and Company.

Enrollment
165th of 232
66 · median 181
Started
2023
with 16 others
Phase 1
76 of 238
2 open now
Registered
205th of 238
by date

Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 165th largest by enrollment of the 232 interventional ones that give a count, is one of 17 that started in 2023, is one of 76 in phase 1, and was the 205th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

10 of the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in participants with T2DM (Part B). The study will last approximately 6 weeks for Part A and approximately 10 weeks for Part B respectively.

03

Conditions studied

  • Healthy
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants who are overtly healthy as determined by medical evaluation (Part A)
  • Participants with T2DM diagnosed greater than 1 year before enrollment (Part A and Part B)
  • Have a within the range of 18.5 to less than or equal to (\<=) 32 kilograms per square meter (kg/m²) for healthy participants and 18.5 to 40 kg/m² for T2DM participants.
  • Male or female participants of nonchildbearing potential

Exclusion criteria

Exclusion Criteria:

  • Have proliferative retinopathy or maculopathy and/or severe neuropathy
  • Have been treated with sulfonylurea, thiazolidinedione, alpha-glucosidase inhibitor, glucagon-like peptide-1 receptor agonist or Insulin within the previous 3 months
  • Have received chronic systemic therapy in the past 3 months
  • Are currently enrolled in another clinical study trial involving medical research, or have participated within the last 30 days in a clinical study involving an product.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    LY3938577 (Part A)

    LY3938577 administered Subcutaneously (SC).

    Drug: LY3938577

  • Placebo comparator
    Placebo (Part A)

    Placebo administered SC.

    Drug: Placebo

  • Active comparator
    Insulin degludec (Part A)

    Insulin degludec administered SC.

    Drug: Insulin degludec

  • Experimental
    LY3938577 (Part B)

    LY3938577 administered SC.

    Drug: LY3938577

  • Active comparator
    Insulin degludec (Part B)

    Insulin degludec administered SC.

    Drug: Insulin degludec

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration

    A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline up to 16 days

  2. Part B: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration

    A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline up to 44 days

  3. Part A: Incidence of Hypoglycemia

    Time frame: Baseline up to 16 days

  4. Part B: Incidence of Hypoglycemia

    Time frame: Baseline up to 44 days

  5. Part A: Number of Participants With Clinically Significant Changes in Vital Signs

    Time frame: Baseline up to 16 days

  6. Part B: Number of Participants With Clinically Significant Changes in Vital Signs

    Time frame: Baseline up to 44 days

  7. Part A: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters

    Time frame: Baseline up to 16 days

  8. Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters

    Time frame: Baseline up to 44 days

Secondary outcomes

  1. Part A and Part B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC)

    Time frame: Part A: Predose up to 16 Days and Part B: Predose up to 44 Days

07

Study locations

3 sites
  • CenExel ACT
    Anaheim, California 92801, United States
  • Qps-Mra, Llc
    Miami, Florida 33143, United States
  • Labcorp CRU
    Dallas, Texas 75247, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jun 2024, 7 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 7 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2023
First posted
Nov 15, 2023
StartActual
Nov 17, 2023
Primary completionActual
Jun 28, 2024
CompletionActual
Jun 28, 2024
Last update
Jul 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06132126
Responsible party
Sponsor
First posted
Nov 15, 2023
Start date
Nov 17, 2023
Primary completion
Jun 28, 2024
Completion
Jun 28, 2024
Last update
Jul 24, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY3938577

Start the discussion